Servier to Buy Day One Biopharmaceuticals for $2.5B

Servier to Buy Day One Biopharmaceuticals in a $2.5B cash tender offer that sets tender mechanics and regulatory timing shaping shareholder supply.

March 06, 2026·2 min read
View all news articles
Flat vector of a biotech capsule joining a molecular lattice to symbolize Servier to Buy Day One Biopharmaceuticals.

KEY TAKEAWAYS

  • Servier offered $21.50 per share via an all-cash tender offer and planned second-step merger.
  • Transaction funded from existing cash and investments with no financing condition.
  • Deal sets an $87.7 million termination fee and a Dec. 6, 2026 outside date.

HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX

Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.

Or subscribe with

Servier agreed on March 6, 2026, to acquire Day One Biopharmaceuticals (NASDAQ: DAWN) in a cash transaction that expands its rare-oncology portfolio and adds Day One’s FDA-approved drug Ojemda to its pipeline.

Deal Terms and Strategic Rationale

Servier set a $21.50 per-share all-cash price for all outstanding common stock, to be executed through a cash tender offer followed by a second-step merger at the same price. The company will fund the purchase from existing cash and investments without a financing condition. The price represents a 68% premium to Day One’s March 5 closing price and an 86% premium to its one-month volume-weighted average price as of that date.

Day One disclosed the agreement in a Form 8-K filing, which included a board fairness opinion and a recommendation that shareholders tender their shares. The filing sets an outside date of December 6, 2026, extendable by 150 days for regulatory approvals, and specifies an $87.7 million termination fee payable to Servier in certain scenarios, such as a superior proposal. The companies plan to file tender-offer materials on a Schedule TO, and Day One will issue a Schedule 14D-9 solicitation and recommendation.

The acquisition advances Servier’s 2030 ambition to develop innovative oncology treatments and expand its rare-oncology offering. It brings Ojemda (tovorafenib), approved by the FDA in 2024 for pediatric low-grade glioma with BRAF alterations, and adds pipeline programs ranging from early-stage to Phase 3 studies targeting RAF/BRAF alterations. Day One focuses on targeted therapies for life-threatening diseases, emphasizing pediatric oncology.

The parties expect to close the transaction in the second quarter of 2026, subject to a majority tender of outstanding shares, U.S. Hart-Scott-Rodino antitrust clearance, and customary closing conditions.

“This acquisition of Day One Biopharmaceuticals marks another decisive step in strengthening Servier’s position in rare oncology,” Olivier Laureau, president of Servier, said in the joint press release.

HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX

Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.

Or subscribe with

Read other top news stories

TeraWulf Q3 2026 Results Lifted by HPC Leases

TeraWulf Q3 2026 Results Lifted by HPC Leases

TeraWulf Q3 2026 results focus on HPC leases and Lake Mariner capacity and cite Google-backed Anthropic financing, shifting trader focus on execution risk.

Broadcom Stock Faces Volatility, Long-Term Case Stands

Broadcom Stock Faces Volatility, Long-Term Case Stands

Broadcom stock drew attention after commentary cited large cash generation and a December capital review, focusing traders on dividends and buybacks.

Hims & Hers Eli Lilly Deal Expands Access to Obesity Drugs

Hims & Hers Eli Lilly Deal Expands Access to Obesity Drugs

Hims & Hers Eli Lilly deal brings Zepbound and Foundayo to the platform at self-pay prices, widening GLP-1 access and reshaping Hims & Hers' commercial mix.

Fox Completes Roku Acquisition

Fox Completes Roku Acquisition

Fox completes Roku acquisition, reshaping Fox's capital base through cash-and-stock consideration and prompting investor shifts around streaming assets.

IREN Q1 FY27 Results Show AI Cloud Surge

IREN Q1 FY27 Results Show AI Cloud Surge

IREN Q1 FY27 Results show AI Cloud surge lifted revenue, backlog while a funded $4.0 billion contracted ARR moved to Jan 2027, tightening positioning.

DraftKings Q3 2026 Earnings Weaken on Predictions Spend

DraftKings Q3 2026 Earnings Weaken on Predictions Spend

DraftKings Q3 2026 Earnings saw revenue growth but a wider adjusted-EBITDA loss after Predictions investment, narrowing 2026 outlook and pressuring flows.